1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Bone Cancer in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Du, C; Guo, R; Li, N; Lu, M; Xie, Q; Yang, Z; Yu, J; Zhai, S; Zhu, H | 1 |
| Du, C; Shao, G; Tian, R; Wang, F; Xie, Q; Yang, Z; Yao, X; Yu, F; Yu, J; Zang, S; Zhang, C; Zhang, P | 1 |
| Chen, L; Chen, Y; Feng, Y; Liu, H; Liu, L; Qiu, L; Wang, L; Wang, Q; Wang, Y | 1 |
| Chen, Y; Liu, G; Qu, G; Wang, L; Xu, T | 1 |
| Chen, Y; Hua, Q; Li, H; Wang, L; Xu, T | 1 |
| Chen, G; Chen, Y; Deng, J; Fan, D; Liu, H; Lu, Z; Mok, GSP; Yang, J | 1 |
| Eppard, E; Essler, M; Kürpig, S; Meisenheimer, M | 1 |
| Hajibeigi, A; Kovacs, Z; Lin, M; Liu, W; Oz, OK; Rostollan, CL; Sun, X | 1 |
| Kawashima, H; Kiyono, Y; Mori, H; Ogawa, K; Saji, H; Shiba, K; Ueda, M; Washiyama, K; Yoshimoto, M | 1 |
| Kanbara, H; Kitamura, Y; Kiwada, T; Odani, A; Ogawa, K; Shiba, K; Takai, K | 1 |
| Al-Nahhas, A | 1 |
| Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A | 1 |
| Baum, RP; Müller, D; Senftleben, S; Wehrmann, C; Zachert, C | 1 |
1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Bone Cancer
| Article | Year |
|---|---|
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2005 |
12 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Bone Cancer
| Article | Year |
|---|---|
Correlation between NEN Bone Metastasis Performance and Tumor Proliferation: 112 Cases of [68Ga]Ga-DOTA-TATE Result Analysis.
Topics: Bone Neoplasms; Cell Proliferation; Gallium; Heterocyclic Compounds, 1-Ring; Humans; Ki-67 Antigen; Lymphatic Metastasis; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Detection of Bone Metastases by
Topics: Bone Neoplasms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gastrointestinal Neoplasms; Humans; Ki-67 Antigen; Neuroendocrine Tumors; Osteolysis; Positron Emission Tomography Computed Tomography; Receptors, Somatostatin; Retrospective Studies | 2022 |
Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study.
Topics: Bone Marrow Diseases; Bone Neoplasms; Humans; Pain; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiopharmaceuticals; Tomography, X-Ray Computed | 2023 |
A New Radiopharmaceutical 225 Ac-DOTA-IBA in the Treatment of a Case of Bone Metastases.
Topics: Bone Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Radioisotopes; Radiopharmaceuticals | 2023 |
177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases.
Topics: Bone Neoplasms; Humans; Ibandronic Acid; Male; Prostatic Neoplasms; Radiopharmaceuticals | 2023 |
Biodistribution and Internal Dosimetry of 68 Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases.
Topics: Bone Neoplasms; Humans; Ibandronic Acid; Positron-Emission Tomography; Radiometry; Tissue Distribution | 2023 |
DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Palliative Care; Quality Control; Radiopharmaceuticals; Zoledronic Acid | 2020 |
An osteoclast-targeting agent for imaging and therapy of bone metastasis.
Topics: Animals; Bone Neoplasms; Cells, Cultured; Diagnostic Imaging; Diphosphonates; Heterocyclic Compounds, 1-Ring; Indium Radioisotopes; Male; Mice; Mice, Inbred BALB C; Osteoclasts; Radionuclide Imaging | 2008 |
Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
Topics: Animals; Bone Neoplasms; Diphosphonates; Drug Stability; Heterocyclic Compounds, 1-Ring; Isotope Labeling; Male; Mice; Radiopharmaceuticals; Radiotherapy Dosage; Tissue Distribution; Yttrium Radioisotopes | 2009 |
Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent.
Topics: Animals; Bone and Bones; Bone Neoplasms; Chelating Agents; Diphosphonates; Drug Stability; Durapatite; Gallium Radioisotopes; Half-Life; Heterocyclic Compounds, 1-Ring; Male; Mice; Organometallic Compounds; Positron-Emission Tomography | 2011 |
Detection of unsuspected bone metastases by ⁶⁸Ga-DOTA: nuclear medicine at the forefront again.
Topics: Bone Neoplasms; Breast Neoplasms; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Neoplasm Micrometastasis; Nuclear Medicine | 2011 |
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
Topics: Adult; Aged; Bone Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Radiotherapy; Radiotherapy Dosage; Receptors, Peptide; Tomography, X-Ray Computed | 2007 |